The lower rating came from HSBC, which cited too much optimism around its new weight-loss pill, and the strength of Novo ...

President Donald Trump is under pressure to decide how widely available anti-obesity drugs should be and whether Medicare ...

HSBC analyst warns of a downside in Eli Lilly stock to $700. Rajesh Kumar cited 'valuation' as his number 1 concern.

Approved by India’s apex drug regulatory body, the weight-loss drug is a once-weekly injection priced at Rs 4,375 for a 5 mg ...

HSBC on Monday double downgraded Eli Lilly and Co. (LLY) stock to ‘Reduce’ from ‘Buy’ and also lowered its price target to ...

The 13-year-old daughter of a Jefferies analyst asked about the effect of GLP-1 oral medications during PepsiCo’s most recent ...

Mounjaro, the new weight loss drug, is gaining popularity in India for its rapid results. Patients report better appetite control, blood sugar management, and significant weight loss.

Novo Nordisk has launched its popular weight-loss drug Wegovy in Thailand, marking its first entry into the Southeast Asian ...

A key House committee is being tasked with finding $880 billion of those cuts, most of which would likely come from Medicaid.

Weight loss drugs like Ozempic, Zepbound and Wegovy are surging in popularity. Now, a new pill from Eli Lilly has taken a ...